

شبكة المعلومات الجامعية التوثيق الإلكتروني والميكروفيلو

بسم الله الرحمن الرحيم





HANAA ALY



شبكة المعلومات الجامعية التوثيق الإلكتروني والميكرونيله



شبكة المعلومات الجامعية التوثيق الالكتروني والميكروفيلم



HANAA ALY



شبكة المعلومات الجامعية التوثيق الإلكترونى والميكروفيلم

جامعة عين شمس التوثيق الإلكتروني والميكروفيلم قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها على هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



HANAA ALY



Anti IFI16 Antibodies in Inflammatory Bowel Disease and Their Variation with Infliximab Therapy in Comparison to Other Modalities of Treatment

Thesis

Submitted for Partial Fulfillment of Master Degree in Onternal Medicine

By

Ebtesam Alaa Mohamed Awad Elshennawy M.B.B.Ch.

Faculty of Medicine - Ain Shams University

Supervised by

Prof. Dr. Emad Ahmed Awad

Professor of Internal Medicine, Gastroenterology and Hepatology Faculty of Medicine - Ain Shams University

Prof. Dr. Wessam Ahmed Ibrahim Mohamed

Professor of Internal Medicine, Gastroenterology and Hepatology Faculty of Medicine - Ain Shams University

Dr. Tari Magdy Aziz George

Lecturer of Internal Medicine, Gastroenterology and Hepatology Faculty of Medicine - Ain Shams University

> Faculty of Medicine Ain Shams University 2021



سورة البقرة الآية: ٣٢

Acknowledgment

First and foremost, I feel always indebted to Allah, the Most Kind and Most Merciful.

I'd like to express my respectful thanks and profound gratitude to **Prof. Dr. Emad Ahmed**Awad, Professor of Internal Medicine, Gastroenterology and Hepatology, Faculty of Medicine - Ain Shams University for his keen guidance, kind supervision, valuable advice and continuous encouragement, which made possible the completion of this work.

I am also delighted to express my deepest gratitude and thanks to **Prof. Dr. Wessam Ahmed Ibrahim Mohamed,** Professor of Internal Medicine,
Gastroenterology and Hepatology, Faculty of Medicine Ain Shams University, for her kind care, continuous supervision, valuable instructions, constant help and great assistance throughout this work.

I am deeply thankful to **Dr. Tari Magdy Aziz George**, Lecturer of Internal Medicine, Gastroenterology and Hepatology, Faculty of Medicine - Ain Shams University, for her great help, active participation and guidance.

I would like to express my hearty thanks to all my family for their support till this work was completed.

Last but not least my sincere thanks and appreciation to all patients participated in this study.

Ebtesam Alaa

Tist of Contents

Title	Page No.
List of Tables	5
List of Figures	7
List of Abbreviations	9
Introduction	1 -
Review of Literature	
☐ Inflammatory Bowel Disease (IBD)	7
□ Anti IFI16	54
Anti IFI 16 in relation to IBD	59
Patients and Methods	64
Results	67
Discussion	96
Conclusion	107
Recommendations	108
Summary	109
References	115
Arabic Summary	

Tist of Tables

Table No.	Title	Page No.
Table (1):	Comparison between UC and CD	28
Table (2):	Comparison of diagnosis for colitis and crohn disease	
Table (3):	Extraintestinal manifestations of in bowel disease	•
Table (4):	Drugs for ulcerative colitis and croh	n disease 53
Table (5):	Demographic data & GIT sympton study population	
Table (6):	Clinical symptoms & associated ma of total study population	
Table (7):	Laboratory investigations for to population.	
Table (8):	Laboratory disease severity & treatment & Anti IFI 16 IgG tit study population	trefor total
Table (9):	Comparison between 3 studie regarding demographic data	
Table (10):	Comparison between clinical syndiagnosis in the 3 study groups	-
Table (11):	Comparison between associated manifestations in the 3 study group	
Table (12):	Comparison between laboratory invin 3 study groups	
Table (13):	Comparison between severity Crohn's, severity for UC & treat groups using test value & Post hoc a severity score for Crohn's	ment in 3 analysis for

Tist of Tables (Cont...)

Table No.	Title	Page No.
Table (14):	Comparison between Anti IFI 16 I groups using Test value & Post ho	-
Table (15):	Correlation between anti IFI 16 different clinical parameters patients	in group I
Table (16):	Comparison between Anti IFI 16 laboratory data using Mann White	~
Table (17):	Correlation between anti IFI 16 different clinical parameters i patients	n group II
Table (18):	Comparison between Anti IFI 16 laboratory data using Mann Whit Kruskal-Wallis test	eney test and
Table (19):	Correlation between anti IFI 16 different clinical parameters in patients	n group III
Table (20):	Comparison between Anti IFI 16 clinical data using Mann White Kruskal-Wallis test	ney test and

List of Figures

Fig. No.	Title	Page No.
Figure (1):	The cross sectional crypt struct large intestine and current UC strategies	therapeutic
Figure (2):	Erythema nodosum in a patient w disease showing the typical deep re	
Figure (3):	Pyoderma gangrenosum in a paulcerative colitis, presenting wirulcer with a sterile central surrounded by purplish-coloured, borders.	th a deep l necrosis indistinct
Figure (4):	Anterior uveitis in a patient wi	
Figure (5):	Primary sclerosing cholangitis in a pulcerative colitis with typical irregula with multifocal strictures in retrograde cholangiopancreatography	ar bile ducts endoscopic
Figure (6):	Granulomatous hepatitis in a pa Crohn's disease	
Figure (7):	CT scan of a patient with Crohn's of granulomatous bronchitis	
Figure (8):	Comparison between 3 studie regarding mean weight	-
Figure (9):	Comparison between 3 studie regarding pulse	-
Figure (10):	Comparison between 3 studio regarding pyrexia.	
Figure (11):	Comparison between 3 studie regarding bowel movement per day	-

Tist of Figures (Cont...)

Fig. No.	T	ītle		Page No	•
Figure (12):	Comparison regarding soft			_	.77
Figure (13):	Comparison regarding block			_	.77
Figure (14):	Comparison regarding abd				
Figure (15):	Comparison regarding ant				.80
Figure (16):	Comparison regarding abd			_	
Figure (17):	Comparison regarding artl				
Figure (18):	Comparison regarding HC				
Figure (19):	Comparison regarding TLC				
Figure (20):	Comparison regarding RSI				
Figure (21):	Comparison regarding CR				
Figure (22):	Comparison regarding seve				
Figure (23):	Comparison regarding seve				
Figure (24):	Comparison regarding dise				.88
Figure (25):	Comparison regarding ant			_	

Tist of Abbreviations

Abb.	Full term
AhRs	Aryl Hydrocarbon Receptors
	Absent in Melanoma 2
	Antimicrobial Peptides
	Anti-Tumour Necrosis Factor
APC	Antigen Presenting Cells
	Anti-Saccaromyces Cer- Evisiae
CBC	Complete Blood Count
CD	Crohn Disease
CGD	Chronic Granulomatosis Disease
CLRs	C-Type Lectin Receptors
COP	Cryptogenic Organizing Pneumonia
<i>DAMPs</i>	Damage-Associated Molecular Patterns
DCs	Dendritic Cells
Fcgbp	Fc - γ $Binding\ Protein$
GI	Gastroint estinal
GWAS	Genome Wide Association Studies
HLA	Human Leucocyte Antigen
HMOS	Human Milk Oligosaccharides
HPB	Hepato- Pancreatobiliary
<i>IBD</i>	Inflammatory Bowel Disease
<i>IDDM</i>	Insulin-Dependent Diabetes Mellitus
<i>IELs</i>	$ Intrae pithelial\ Lymphocytes$
IELs	$ In trae pithelial\ Lymphocytes$
<i>IL-18</i>	Interleukin-18

Tist of Abbreviations (Cont...)

Abb.	Full term
<i>IL-1β</i>	Interleukin- $1eta$
•	Linkage Disequilibrium
<i>LP</i>	Lamina Propria
LPS	Lipopoly saccharide
<i>LRR</i>	Leucin Rich Repeats
LTA	Lipoteichoic Acid
<i>M</i>	Microfold
<i>MDP</i>	Muramyle Dipeptide
<i>MHC</i>	Major Histocompatibility Complex
NADPH	Nicotinamide Adenine Dinucleotide Phosphate
<i>NLR</i>	Containing Receptors
<i>NLRP</i>	NOD-Like Receptor-Pyrin-Containing Proteins
NOD	Nucleotide-Binding Oligomerization Domain
NOD2	Nucleotide-Binding Oligomerization Domain-Containing Protein 2
OAS	Oligoadenylate Synthase
<i>PAMPs</i>	Pathogen-Associated Molecular Patterns
PRRs	Pattern Recognition Receptors
<i>PSC</i>	Primary Sclerosing Cholangitis
<i>RELMβ</i>	Resistin-Like Molecule eta
RIG-1	Retinoic Acid-Inducible Gene 1
SD	Standard Deviation

Tist of Abbreviations (Cont...)

Abb.	Full term
SNPs	Single Nucleotide Polymorphisms
SPSS	Statistical Package for Special Science
TLRS	Toll-Like Receptors
TLRs	Toll-Like Receptors
TNF	Tumor Necrosis Factor
UC	Ulcerative Colitis
<i>VIP</i>	Vasoactive Intestinal Peptide

Introduction

he gastrointestinal (GI) tract, found in humans and animals, represents a unique environment extending from the mouth to the anus (*Cheng et al.*, 2010). The intestine, a muscular tube of the digestive system stretching from the stomach to the anus, consists of the small and large intestine. It is involved in food digestion as well as in enzyme and hormone production (e.g. cholecystokinin that stimulates the secretion of pancreatic enzymes and bile). It plays an important role in fighting pathogens and in regulating the body's water balance (*Kiela and Ghishan*, 2016) and it has been demonstrated that the gut microflora potentially contributes to proteolysis in the human colon (*Valdes et al.*, 2018).

The large intestine, which is involved in the transport of water and electrolytes and the storage of faecal waste in the sigmoid colon and rectum prior to elimination (*Cheng et al.*, 2010), is implicated in the processing of indigestible food after most nutrients are absorbed in the small intestine (*Azzouz and Sharma*, 2018). Many disorders affect the colon's ability to work properly.

Inflammatory bowel disease (IBD) refers to ulcerative colitis (UC) and Crohn disease (CD); 2 chronic idiopathic inflammatory diseases which differ in pathophysiology, affected parts of the gastrointestinal (GI) tract, symptoms, complications, disease course and management. Clinical,